ImmunityBio Says ANKTIVA Combo Outperformed Rival Bladder Cancer Therapies
ImmunityBio, Inc. Common Stock · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · Now $7.52
-7.0% in 3d after detection
Post-detection moves
1h
—
1d
+3.7%
3d
-7.0%
7d
-3.1%
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS